

LONDON/FRANKFURT, June 10 (Reuters) - Pfizer is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter ...


* Tolerability remains key challenge, with most GLP-1 drugs causing significant side effects


(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday.


* Deal values cancer drug developer Nuvalent at $124 per share


(Alliance News) - AstraZeneca PLC on Monday announced positive results from the Vista and Solstice phase IIb trials of elecoglipron, an oral small mol...


(Alliance News) - GSK agrees to buy US cancer treatment firm Nuvalent for USD10.6 billion, AstraZeneca advances its own weight-loss treatment while Be...


* AstraZeneca advancing obesity strategy with experimental pill